Detailed Coverage

Dr. Reddy's Q1FY27 Results: Profit Slides Amidst US Weakness and Operational Costs

Net Profit: ₹436 crore (down 69.1% YoY)
Net Sales: ₹8,100 crore (down 5.5% YoY)

Reader Takeaway: Strong domestic growth is offset by US headwinds and supply chain issues.

What just happened

Dr. Reddy's Laboratories reported a significant decline in its financial performance for the first quarter of FY2027. Net sales decreased by 5.5% year-on-year to ₹8,100 crore. Net profit saw a sharp fall of 69.1%, settling at ₹436 crore. The company's EBITDA margin compressed to 10.6%.

Why this matters

The steep drop in profitability and revenue signals challenges for the company, particularly from its key North American market. The decline in margins and profit raises concerns about the company's ability to manage operating costs and product mix effectively in the near term.

The backstory

In Q1FY27, consolidated revenue was ₹8,100 crore, down 5.5% YoY. This was primarily due to a 35% drop in North America, attributed to lower lenalidomide sales and generic price erosion. However, the India business grew 17% and Emerging Markets by 31%, partially cushioning the decline. Net profit plunged 69.1% to ₹436 crore, impacted by an adverse product mix and higher operating costs.

What changes now

An analyst's SELL recommendation with a target price of ₹1,070 suggests a cautious outlook. The company faces near-term operational costs and margin pressure. Investors will be closely watching the resolution of FDA observations at the Bachupally facility and the resumption of semaglutide supplies.

Risks to watch

Key risks include 7 FDA Form 483 observations at the Bachupally site, potentially affecting pipeline assets. The disruption of semaglutide API supplies, with a halt until November 2026 and a ₹240 crore provision, is a significant operational challenge. Generic price erosion in the US injectables market also poses a competitive threat.

Peer comparison

(No direct peer comparison data provided in the filing.)

Context metrics (time-bound)

• North America revenue declined by 35.4% YoY.
• India business revenue grew by 16.8% YoY.
• Emerging Markets revenue grew by 30.5% YoY.
• Semaglutide supply is expected to resume by November 2026.

What to track next

Investors should monitor the company's progress in addressing the FDA observations at the Bachupally facility. The successful resumption of semaglutide supplies and the company's ability to return EBITDA margins to the 18-20% range will be critical indicators.